Abstract
The aims of this research were to (1) create a curated universal database of intravitreal volumes of distribution (Vss, ivt) and clearances (CLivt) of small molecular weight compounds and macromolecules and (2) to develop quantitative structure property relationship (QSPR) and pharmacokinetic models for the estimation of vitreal drug concentrations based on the compound structure.Vss, ivt and CLivt values were determined from the available literature on intravitreal drug administration using compartmental models and curve fitting. A simple QSPR model for CLivt of small molecular weight compounds was obtained with two descriptors: LogD7.4 and hydrogen bond donor capacity. The model predicted the internal and external test sets reliably with a mean fold error of 1.50 and 1.33, respectively (Q2Y=0.62). For 80% of the compounds the Vss, ivt was 1.18–2.28ml; too narrow range for QSPR model building. Integration of the estimated Vss, ivt and predicted CLivt parameters into pharmacokinetic simulation models allows prediction of vitreous drug concentrations after intravitreal administration.The present work presents for the first time a database of CLivt and Vss, ivt values and the dependence of the CLivt values on the molecular structure. The study provides also useful in silico tools to investigate a priori the intravitreal pharmacokinetic profiles for intravitreally injected candidate compounds and drug delivery systems.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Pharmaceutics and Biopharmaceutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.